EP4036114A4 - LIFE-SPECIFIC BINDING MOLECULE AND USE THEREOF - Google Patents

LIFE-SPECIFIC BINDING MOLECULE AND USE THEREOF Download PDF

Info

Publication number
EP4036114A4
EP4036114A4 EP20870311.6A EP20870311A EP4036114A4 EP 4036114 A4 EP4036114 A4 EP 4036114A4 EP 20870311 A EP20870311 A EP 20870311A EP 4036114 A4 EP4036114 A4 EP 4036114A4
Authority
EP
European Patent Office
Prior art keywords
lif
binding molecule
molecule specific
specific
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20870311.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4036114A1 (en
Inventor
Qinghao Liu
Jun Tao
Wenlai Zhou
Shanshan HE
Haiyan Yang
Hongling Wang
Guiqun YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jacobio Pharmaceuticals Co Ltd
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of EP4036114A1 publication Critical patent/EP4036114A1/en
Publication of EP4036114A4 publication Critical patent/EP4036114A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP20870311.6A 2019-09-29 2020-09-28 LIFE-SPECIFIC BINDING MOLECULE AND USE THEREOF Pending EP4036114A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019108904 2019-09-29
CN2020077049 2020-02-27
PCT/CN2020/118247 WO2021057991A1 (zh) 2019-09-29 2020-09-28 对lif具有特异性的结合分子及其用途

Publications (2)

Publication Number Publication Date
EP4036114A1 EP4036114A1 (en) 2022-08-03
EP4036114A4 true EP4036114A4 (en) 2023-11-08

Family

ID=75165589

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20870311.6A Pending EP4036114A4 (en) 2019-09-29 2020-09-28 LIFE-SPECIFIC BINDING MOLECULE AND USE THEREOF

Country Status (13)

Country Link
US (1) US20210403582A1 (pt)
EP (1) EP4036114A4 (pt)
JP (1) JP2022550121A (pt)
KR (1) KR20220087457A (pt)
CN (1) CN114040924A (pt)
AU (1) AU2020354255A1 (pt)
BR (1) BR112022005909A2 (pt)
CA (1) CA3156080A1 (pt)
CL (1) CL2022000752A1 (pt)
IL (1) IL291710A (pt)
MX (1) MX2022003762A (pt)
TW (1) TWI770619B (pt)
WO (1) WO2021057991A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022228514A1 (zh) * 2021-04-29 2022-11-03 北京浩古元方生物医药科技有限公司 抗人白血病抑制因子抗体及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
WO2019243893A1 (en) * 2018-06-18 2019-12-26 Mosaic Biomedicals Slu Methods of quantifying lif and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EP1872124A4 (en) * 2005-04-19 2008-06-11 Prediction Sciences Llc DIAGNOSTIC MARKERS FOR THE TREATMENT AND EVOLUTION OF BREAST CANCER AND METHODS OF USE
US20080280297A1 (en) * 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
TW201623329A (zh) * 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
WO2019243893A1 (en) * 2018-06-18 2019-12-26 Mosaic Biomedicals Slu Methods of quantifying lif and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors", CINICALTRIALS.GOV, 30 March 2018 (2018-03-30), XP055648550, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03490669?V_3=View#StudyPageTop> [retrieved on 20191203] *
BORAZANCI E. ET AL: "Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors", ESMO OPEN : CANCER HORIZONS, vol. 7, no. 4, 1 August 2022 (2022-08-01), London, pages 100530, XP093084517, ISSN: 2059-7029, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/778034/1-s2.0-S2059702922X00045/1-s2.0-S205970292200151X/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEAcaCXVzLWVhc3QtMSJIMEYCIQDG+WiRLt3BODWKvBBK4ibrDk0uaKg6Y489sdgszhYRDAIhAIkQZSn91bS2YgqSVWbUd8I+2z7mof8J30edoBPEyTubKrwFCPD//////////wEQBRoMMDU5MDAzNTQ2ODY1IgxH8> DOI: 10.1016/j.esmoop.2022.100530 *
JEANNE MAGRAM ET AL: "LIF as a novel cancer immunotherapy target: Modulating the tumor microenvironment with MSC-1, a humanized anti-LIF monoclonal antibody", INTERNET CITATION, 1 January 2018 (2018-01-01), pages 1, XP002779777, Retrieved from the Internet <URL:http://northernbiologics.com/wp-content/uploads/2017/10/AACR-Molecular-targets-2017-poster.pdf> [retrieved on 20180406] *
XIAOYAN LI ET AL: "LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway", ONCOTARGET, 15 February 2014 (2014-02-15), United States, pages 788, XP055156398, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/24553191> DOI: 10.18632/oncotarget.1772 *

Also Published As

Publication number Publication date
EP4036114A1 (en) 2022-08-03
BR112022005909A2 (pt) 2022-10-11
JP2022550121A (ja) 2022-11-30
IL291710A (en) 2022-05-01
CN114040924A (zh) 2022-02-11
MX2022003762A (es) 2022-06-24
TW202112813A (zh) 2021-04-01
KR20220087457A (ko) 2022-06-24
CL2022000752A1 (es) 2022-11-18
CA3156080A1 (en) 2021-04-01
TWI770619B (zh) 2022-07-11
AU2020354255A1 (en) 2022-04-21
WO2021057991A1 (zh) 2021-04-01
US20210403582A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
EP3870223A4 (en) MULTIVALENT IGM AND IGA-FC BASED BINDING MOLECULES
EP3665303A4 (en) CLEC9A BINDING INGREDIENTS AND USES THEREOF
EP3613771A4 (en) FOR LRIG-1 PROTEIN SPECIFIC BINDING MOLECULE AND USE OF IT
EP3655432A4 (en) BINDING PROTEIN 1
EP3743448A4 (en) XCR1 BINDING AGENTS AND USES THEREOF
EP3927740A4 (en) ALBUMIN-BINDING ANTIBODIES AND USE THEREOF
EP3935183A4 (en) CD40-BINDING ANTIBODIES AND THEIR USES
EP3917542A4 (en) MULTISPECIFIC BINDING PROTEINS
EP3964531A4 (en) PROTEIN MOLECULE AND USE THEREOF
EP3749295A4 (en) FIBROBLAST BINDING AGENTS AND USES THEREOF
EP3997230A4 (en) CLAUDIN-6 BINDING MOLECULES AND USES THEREOF
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
EP3957478A4 (en) BINDING BAND
EP4013789A4 (en) VISTA BINDING ANTIBODIES AND USES THEREOF
EP3981790A4 (en) CD73-SPECIFIC BINDING MOLECULE AND USE OF THE BINDING MOLECULE
EP3882266A4 (en) LRIG-1 PROTEIN SPECIFIC BINDING MOLECULE AND USE THEREOF
GB201901305D0 (en) Specific binding molecules
IL291710A (en) LIF-SPECIFIC BINDING COMPOUND AND USE THEREOF
EP4033956A4 (en) CLAP APPLICATOR
IL304317A (en) tgf–beta–rii binding proteins
EP3781204A4 (en) BINDING MOLECULES
EP3803401A4 (en) BROAD-SPECTRUM KINASE BINDERS
EP4077385A4 (en) CXCL10-BINDING PROTEINS AND USES THEREOF
IL286929A (en) Tri-specific binding proteins, methods, and their use
EP3976102A4 (en) IMMUNE-INHIBITION ANTI-GAL9 BINDING MOLECULES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220331

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231011

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20231005BHEP

Ipc: A61K 39/395 20060101ALI20231005BHEP

Ipc: C12N 5/10 20060101ALI20231005BHEP

Ipc: C12N 15/63 20060101ALI20231005BHEP

Ipc: C12N 15/13 20060101ALI20231005BHEP

Ipc: C07K 16/24 20060101AFI20231005BHEP